Literature DB >> 17967305

Rectal dose-volume differences using proton radiotherapy and a rectal balloon or water alone for the treatment of prostate cancer.

Carlos Vargas1, Chaitali Mahajan, Amber Fryer, Daniel Indelicato, Randal H Henderson, Craig McKenzie, David Horne, Angela Chellini, Paula Lawlor, Zuofeng Li, Kenneth Oliver, Sameer Keole.   

Abstract

PURPOSE: To describe dose-volume values with the use of water alone vs. a rectal balloon (RB) for the treatment of prostate cancer with proton therapy.
MATERIALS AND METHODS: We analyzed 30 proton plans for 15 patients who underwent CT and MRI scans with an RB or water alone. Simulation was performed with a modified MRI endorectal coil and an RB with 100 mL of water or water alone. Doses of 78-82 gray equivalents were prescribed to the planning target volume. The two groups were compared for three structures: rectum, rectal wall (RW), and rectal wall 7 cm (RW7) at the level of the planning target volume.
RESULTS: Rectum and RW volumes radiated to low, intermediate, and high doses were small: rectum V10, 33.7%; V50, 17.3%; and V70, 10.2%; RW V10, 32.4%; V50, 20.4%; and V70, 14.6%. The RB effectively increased the rectal volume for all cases (139.8 +/- 44.9 mL vs. 217.7 +/- 32.2 mL (p < 0.001). The RB also decreased the volume of the rectum radiated to doses V10-V65 (p < or = 0.05); RW for V10-V50; and RW7 for V10-V35. An absolute rectum V50 improvement >5% was seen for the RB in 5 of 15 cases, for a benefit of 9.2% +/- 2.3% compared with 2.4% +/- 1.3% for the remaining 10 cases (p < 0.001). Similar benefit was seen for the rectal wall. No benefit was seen for doses > or =70 gray equivalents for the rectum, RW, or RW7. No benefit of < or =1% was seen with an RB in 46% for the rectum V70 and in 40% for the rectal wall V70.
CONCLUSIONS: Rectum and rectal wall doses with proton radiation were low whether using water or an RB. Selected patients will have a small but significant advantage with an RB; however, water alone was well tolerated and will be an alternative for most patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967305     DOI: 10.1016/j.ijrobp.2007.04.075

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon.

Authors:  Curtiland Deville; Stefan Both; Viet Bui; Wei-Ting Hwang; Kay-See Tan; Mattia Schaer; Zelig Tochner; Neha Vapiwala
Journal:  Radiat Oncol       Date:  2012-05-23       Impact factor: 3.481

2.  Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger.

Authors:  Bradford S Hoppe; Romaine C Nichols; Randal H Henderson; Christopher G Morris; Christopher R Williams; Joseph Costa; Robert B Marcus; William M Mendenhall; Zuofeng Li; Nancy P Mendenhall
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

3.  Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer.

Authors:  Hong F Xiang; Hsiao-Ming Lu; Jason A Efstathiou; Anthony L Zietman; Ricardo De Armas; Kathryn Harris; B Nicolas Bloch; Muhammad Mustafa Qureshi; Sean Keohan; Ariel E Hirsch
Journal:  J Appl Clin Med Phys       Date:  2017-04-13       Impact factor: 2.102

Review 4.  Management of Motion and Anatomical Variations in Charged Particle Therapy: Past, Present, and Into the Future.

Authors:  Julia M Pakela; Antje Knopf; Lei Dong; Antoni Rucinski; Wei Zou
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

5.  Impact of rectal balloon-filling materials on the dosimetry of prostate and organs at risk in photon beam therapy.

Authors:  Shiv P Srivastava; Indra J Das; Arvind Kumar; Peter A S Johnstone; Chee-Wai Cheng
Journal:  J Appl Clin Med Phys       Date:  2013-01-07       Impact factor: 2.102

6.  Effectiveness of a novel gas-release endorectal balloon in the removal of rectal gas for prostate proton radiation therapy.

Authors:  Landon S Wootton; Rajat J Kudchadker; A Sam Beddar; Andrew K Lee
Journal:  J Appl Clin Med Phys       Date:  2012-09-06       Impact factor: 2.102

7.  Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer.

Authors:  Carlos E Vargas; Matthew Q Schmidt; Joshua R Niska; William F Hartsell; Sameer R Keole; Lucius Doh; John Han-Chih Chang; Christopher Sinesi; Rossio Rodriquez; Mark Pankuch; Gary L Larson
Journal:  Adv Radiat Oncol       Date:  2018-02-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.